1. Home
  2. ENRDW vs ERNAW Comparison

ENRDW vs ERNAW Comparison

Compare ENRDW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Einride AB Warrants

ENRDW

Einride AB Warrants

N/A

Current Price

$0.47

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Logo Ernexa Therapeutics Inc. Warrants

ERNAW

Ernexa Therapeutics Inc. Warrants

N/A

Current Price

$0.11

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ENRDW
ERNAW
Founded
N/A
N/A
Country
Sweden
United States
Employees
N/A
5
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ENRDW
ERNAW
Price
$0.47
$0.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
101.1K
9.1K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$0.02
52 Week High
$0.73
$0.23

Technical Indicators

Market Signals
Indicator
ENRDW
ERNAW
Relative Strength Index (RSI) 31.44 53.27
Support Level N/A $0.10
Resistance Level $0.72 $0.23
Average True Range (ATR) 0.09 0.03
MACD -0.01 0.00
Stochastic Oscillator 6.70 75.35

Price Performance

Historical Comparison
ENRDW
ERNAW

About ENRDW Einride AB Warrants

Einride AB is a technology company that develops and operates digital, electric, and autonomous freight solutions. Its platform includes planning and optimization tools, autonomous technologies, electric heavy-duty vehicle fleets, and charging infrastructure. It serves customers across North America, Europe, and the Middle East. The company's solutions support customers in transitioning logistics operations to electric and autonomous systems. Its business model includes Freight-Capacity-as-a-Service (FCaaS) and Software-as-a-Service (SaaS) offerings delivered through an AI-based platform that manages aspects of electric and autonomous operations.

About ERNAW Ernexa Therapeutics Inc. Warrants

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: